Phosphodiesterase IV inhibitor - Celltech/Merck

Drug Profile

Phosphodiesterase IV inhibitor - Celltech/Merck

Alternative Names: PDE4 inhibitor - Celltech/Merck

Latest Information Update: 21 Sep 2007

Price : $50

At a glance

  • Originator Celltech Group
  • Developer Merck & Co
  • Class
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 21 Jul 2003 Phase-I clinical trials in Chronic obstructive pulmonary disease in USA (PO)
  • 21 Jul 2003 Phase-I clinical trials in Asthma in USA (PO)
  • 08 May 2003 Discontinued - Phase-II for Chronic obstructive pulmonary disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top